Analysts expect Iovance Biotherapeutics, Inc. to report revenue of 137.81 M for Q4 26, against a range of 132.77 M to 142.85 M. The most recent reported quarter, Q3 26, came in at 121.47 M, a 0.8% miss against the 122.39 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 58.55 M | 73.69 M | 49.32 M | 59.95 M | 67.45 M | 86.71 M | 71.43 M | 99.31 M | 121.47 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 53.09 M | 77.28 M | 88.75 M | 76.15 M | 74.90 M | 88.11 M | 79.89 M | 93.04 M | 127.64 M | 142.85 M | 149.97 M | 162.99 M | 159.76 M | 185.21 M | 215.99 M | 239.61 M | 245.20 M | |||||||||
| Low Estimate | 47.41 M | 71.81 M | 82.25 M | 66.44 M | 65.46 M | 78.75 M | 69.23 M | 76.90 M | 117.14 M | 132.77 M | 127.65 M | 140.38 M | 137.49 M | 167.93 M | 194.98 M | 214.59 M | 229.53 M | |||||||||
| Consensus Estimate | 50.25 M | 74.54 M | 85.50 M | 71.29 M | 70.18 M | 83.43 M | 74.56 M | 84.97 M | 122.39 M | 137.81 M | 138.81 M | 151.68 M | 148.63 M | 176.57 M | 205.48 M | 227.10 M | 237.37 M |
Analysts expect Iovance Biotherapeutics, Inc. to report earnings per share of -0.08 for Q4 26, against a range of -0.09 to -0.07. The most recent reported quarter, Q3 26, came in at -0.05, a 45.7% beat against the -0.09 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.28 | -0.26 | -0.36 | -0.33 | -0.25 | -0.18 | -0.19 | -0.11 | -0.05 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.31 | -0.24 | -0.21 | -0.25 | -0.23 | -0.15 | -0.13 | -0.11 | -0.08 | -0.07 | -0.08 | -0.06 | 0.00 | 0.01 | 0.00 | 0.05 | 0.10 | |||||||||
| Low Estimate | -0.33 | -0.26 | -0.25 | -0.29 | -0.27 | -0.17 | -0.15 | -0.13 | -0.10 | -0.09 | -0.08 | -0.06 | 0.00 | 0.01 | 0.00 | 0.05 | 0.08 | |||||||||
| Consensus Estimate | -0.32 | -0.25 | -0.23 | -0.27 | -0.25 | -0.16 | -0.14 | -0.12 | -0.09 | -0.08 | -0.08 | -0.06 | 0.00 | 0.01 | 0.00 | 0.05 | 0.09 |
Pull Wall Street consensus for Iovance Biotherapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IOVA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IOVA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IOVA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();